272 related articles for article (PubMed ID: 31426601)
1. The uPAR System as a Potential Therapeutic Target in the Diseased Eye.
Cammalleri M; Dal Monte M; Pavone V; De Rosa M; Rusciano D; Bagnoli P
Cells; 2019 Aug; 8(8):. PubMed ID: 31426601
[TBL] [Abstract][Full Text] [Related]
2. The urokinase-type plasminogen activator system as drug target in retinitis pigmentosa: New pre-clinical evidence in the rd10 mouse model.
Cammalleri M; Dal Monte M; Locri F; Pecci V; De Rosa M; Pavone V; Bagnoli P
J Cell Mol Med; 2019 Aug; 23(8):5176-5192. PubMed ID: 31251468
[TBL] [Abstract][Full Text] [Related]
3. The urokinase/urokinase receptor system in retinal neovascularization: inhibition by A6 suggests a new therapeutic target.
McGuire PG; Jones TR; Talarico N; Warren E; Das A
Invest Ophthalmol Vis Sci; 2003 Jun; 44(6):2736-42. PubMed ID: 12766081
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of choroidal neovascularization by a peptide inhibitor of the urokinase plasminogen activator and receptor system in a mouse model.
Das A; Boyd N; Jones TR; Talarico N; McGuire PG
Arch Ophthalmol; 2004 Dec; 122(12):1844-9. PubMed ID: 15596589
[TBL] [Abstract][Full Text] [Related]
5. Suppression of the uPAR-uPA system retards angiogenesis, invasion, and in vivo tumor development in pancreatic cancer cells.
Gorantla B; Asuthkar S; Rao JS; Patel J; Gondi CS
Mol Cancer Res; 2011 Apr; 9(4):377-89. PubMed ID: 21389187
[TBL] [Abstract][Full Text] [Related]
6. Diabetic Retinopathy in the Spontaneously Diabetic Torii Rat: Pathogenetic Mechanisms and Preventive Efficacy of Inhibiting the Urokinase-Type Plasminogen Activator Receptor System.
Cammalleri M; Dal Monte M; Locri F; Marsili S; Lista L; De Rosa M; Pavone V; Rusciano D; Bagnoli P
J Diabetes Res; 2017; 2017():2904150. PubMed ID: 29464181
[TBL] [Abstract][Full Text] [Related]
7. Plasminogen activator inhibitor-1 as a measure of vascular remodelling in breast cancer.
Fox SB; Taylor M; Grøndahl-Hansen J; Kakolyris S; Gatter KC; Harris AL
J Pathol; 2001 Sep; 195(2):236-43. PubMed ID: 11592104
[TBL] [Abstract][Full Text] [Related]
8. Gaining insight on mitigation of rubeosis iridis by UPARANT in a mouse model associated with proliferative retinopathy.
Locri F; Pesce NA; Aronsson M; Cammalleri M; De Rosa M; Pavone V; Bagnoli P; Kvanta A; Dal Monte M; André H
J Mol Med (Berl); 2020 Nov; 98(11):1629-1638. PubMed ID: 32940719
[TBL] [Abstract][Full Text] [Related]
9. Haemostatic factors occupy new territory: the role of the urokinase receptor system and kininogen in inflammation.
Chavakis T; Kanse SM; May AE; Preissner KT
Biochem Soc Trans; 2002 Apr; 30(2):168-73. PubMed ID: 12023845
[TBL] [Abstract][Full Text] [Related]
10. Targeting of urokinase plasminogen activator receptor in human pancreatic carcinoma cells inhibits c-Met- and insulin-like growth factor-I receptor-mediated migration and invasion and orthotopic tumor growth in mice.
Bauer TW; Liu W; Fan F; Camp ER; Yang A; Somcio RJ; Bucana CD; Callahan J; Parry GC; Evans DB; Boyd DD; Mazar AP; Ellis LM
Cancer Res; 2005 Sep; 65(17):7775-81. PubMed ID: 16140945
[TBL] [Abstract][Full Text] [Related]
11. The urokinase/urokinase receptor system mediates the IgG immune complex-induced inflammation in lung.
Shushakova N; Eden G; Dangers M; Menne J; Gueler F; Luft FC; Haller H; Dumler I
J Immunol; 2005 Sep; 175(6):4060-8. PubMed ID: 16148155
[TBL] [Abstract][Full Text] [Related]
12. [The urokinase-type plasminogen activator system and its role in tumor progression].
Kugaevskaya EV; Gureeva TA; Timoshenko OS; Solovyeva NI
Biomed Khim; 2018 Nov; 64(6):472-486. PubMed ID: 30632975
[TBL] [Abstract][Full Text] [Related]
13. Expression of urokinase-type plasminogen activator and its receptor in keloids.
Leake D; Doerr TD; Scott G
Arch Otolaryngol Head Neck Surg; 2003 Dec; 129(12):1334-8. PubMed ID: 14676162
[TBL] [Abstract][Full Text] [Related]
14. Regulation and role of urokinase plasminogen activator in vascular remodelling.
Tkachuk V; Stepanova V; Little PJ; Bobik A
Clin Exp Pharmacol Physiol; 1996 Sep; 23(9):759-65. PubMed ID: 8911711
[TBL] [Abstract][Full Text] [Related]
15. Downregulation of uPA/uPAR inhibits intermittent hypoxia-induced epithelial-mesenchymal transition (EMT) in DAOY and D283 medulloblastoma cells.
Gupta R; Chetty C; Bhoopathi P; Lakka S; Mohanam S; Rao JS; Dinh DE
Int J Oncol; 2011 Mar; 38(3):733-44. PubMed ID: 21181094
[TBL] [Abstract][Full Text] [Related]
16. Binding of human urokinase-type plasminogen activator to its receptor: residues involved in species specificity and binding.
Quax PH; Grimbergen JM; Lansink M; Bakker AH; Blatter MC; Belin D; van Hinsbergh VW; Verheijen JH
Arterioscler Thromb Vasc Biol; 1998 May; 18(5):693-701. PubMed ID: 9598826
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of plasma urokinase-type plasminogen activator and urokinase-type plasminogen-activator receptor in patients with acute and chronic hepatitis B.
Zhou H; Wu X; Lu X; Chen G; Ye X; Huang J
Thromb Res; 2009; 123(3):537-42. PubMed ID: 18691743
[TBL] [Abstract][Full Text] [Related]
18. Antiangiogenic Effectiveness of the Urokinase Receptor-Derived Peptide UPARANT in a Model of Oxygen-Induced Retinopathy.
Dal Monte M; Rezzola S; Cammalleri M; Belleri M; Locri F; Morbidelli L; Corsini M; Paganini G; Semeraro F; Cancarini A; Rusciano D; Presta M; Bagnoli P
Invest Ophthalmol Vis Sci; 2015 Apr; 56(4):2392-407. PubMed ID: 25766585
[TBL] [Abstract][Full Text] [Related]
19. Urokinase plasminogen activator system: a multifunctional role in tumor progression and metastasis.
Choong PF; Nadesapillai AP
Clin Orthop Relat Res; 2003 Oct; (415 Suppl):S46-58. PubMed ID: 14600592
[TBL] [Abstract][Full Text] [Related]
20. Pericellular proteolysis by leukocytes and tumor cells on substrates: focal activation and the role of urokinase-type plasminogen activator.
Kindzelskii AL; Amhad I; Keller D; Zhou MJ; Haugland RP; Garni-Wagner BA; Gyetko MR; Todd RF; Petty HR
Histochem Cell Biol; 2004 Apr; 121(4):299-310. PubMed ID: 15042374
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
